25.03.2025 09:04 | AZN | AstraZeneca highlights new Tagrisso data in lung cancer trials
| Alliance |
21.03.2025 14:25 | AGL, AZN | Angle hails successful completion of Eisai contract; approval by Astra | Alliance |
21.03.2025 11:27 | AZN | AstraZeneca to invest USD2.5 billion in new Beijing strategic centre | Alliance |
21.03.2025 10:58 | AZN | AZN invests $2.5bn in Beijing R&D & manufacturing | RNS |
20.03.2025 14:31 | AZN, HCM | IN BRIEF: Hutchmed highlights positive lung cancer test results | Alliance |
17.03.2025 14:22 | SHEL, AZN, MHN | UK dividends calendar - next 7 days | Alliance |
17.03.2025 08:57 | AZN | AstraZeneca to pay up to USD1 billion for cell therapy firm, EsoBiotec | Alliance |
17.03.2025 07:10 | AZN | Eneboparatide Phase III trial met primary endpoint | RNS |
17.03.2025 07:05 | AZN | Imfinzi approved in EU for limited-stage SCLC | RNS |
17.03.2025 07:00 | AZN | AstraZeneca to acquire EsoBiotec | RNS |
12.03.2025 18:00 | AZN | Holding(s) in Company | RNS |
07.03.2025 15:00 | AZN | Director/PDMR Shareholding | RNS |
07.03.2025 11:00 | AZN | Notice of AGM | RNS |
07.03.2025 09:59 | AZN | AstraZeneca finds Imfinzi improves survival rates for gastric cancers | Alliance |
07.03.2025 07:00 | AZN | Imfinzi improved EFS in early-stage gastric cancer | RNS |
06.03.2025 15:00 | AZN | Director/PDMR Shareholding | RNS |
05.03.2025 15:00 | AZN | Director/PDMR Shareholding | RNS |
03.03.2025 15:00 | AZN | Total Voting Rights | RNS |
03.03.2025 11:13 | AZN | AstraZeneca lung cancer therapy Imfinzi recommended for EU approval | Alliance |
03.03.2025 07:00 | AZN | Imfinzi recommended for EU approval for AEGEAN | RNS |
28.02.2025 15:26 | AZN | AstraZeneca breast cancer therapy wins recommendation for EU approval | Alliance |
28.02.2025 13:00 | AZN | Enhertu recommended in EU in post-ET breast cancer | RNS |
26.02.2025 09:27 | AZN | AstraZeneca's camizestrant has benefit in advanced breast cancer trial | Alliance |
26.02.2025 07:00 | AZN | Camizestrant improved PFS in 1L HR+ breast cancer | RNS |
19.02.2025 07:00 | AZN | Filing of Form 20-F with SEC | RNS |
18.02.2025 11:00 | AZN | Annual Financial Report | RNS |
18.02.2025 07:00 | AZN | Directorate Change | RNS |
13.02.2025 14:02 | RESI, PRSR, MHN | UK dividends calendar - next 7 days | Alliance |
13.02.2025 09:35 | CTEC, AZN, SMIN | LONDON BROKER RATINGS: UBS raises AstraZeneca to 'buy' | Alliance |
12.02.2025 09:58 | IAG, ADM, EZJ | LONDON BROKER RATINGS: Morgan Stanley likes Astra; HSBC cuts Spectris | Alliance |
11.02.2025 09:52 | STAN, NWG, LLOY | LONDON BROKER RATINGS: Peel Hunt raises Fevertree to 'hold' | Alliance |
10.02.2025 09:59 | IAG, AZN, AGL | LONDON BROKER RATINGS: Deutsche Bank raises Victrex, cuts Fevertree | Alliance |
06.02.2025 08:42 | AZN | Cancer drugs help drive fourth-quarter sales beat at AstraZeneca | Alliance |
06.02.2025 07:00 | AZN | Final Results | RNS |
04.02.2025 10:41 | AZN, GSK, INDV | IN BRIEF: Indivior completes USD100 million share buyback | Alliance |
03.02.2025 17:00 | AZN | Total Voting Rights | RNS |
03.02.2025 08:34 | AZN | AstraZeneca's Imfinzi endorsed for EU approval for lung cancer care | Alliance |
03.02.2025 07:00 | AZN | Imfinzi recommended for EU approval for LS-SCLC | RNS |
31.01.2025 18:20 | AZN | AstraZeneca pulls UK investment after dispute over Government support | Alliance |
30.01.2025 11:26 | JTC, CPG, WOSG | UK earnings, trading statements calendar - next 7 days | Alliance |
28.01.2025 13:43 | AZN, API, FCSS | EXECUTIVE CHANGES: Smithson changes chairs; British Land taps new COO | Alliance |
28.01.2025 07:00 | AZN | Enhertu approved in US for breast cancer post ET | RNS |
28.01.2025 07:00 | AZN | AstraZeneca's and Daiichi Sankyo's Enhertu wins new approval in US | Alliance |
23.01.2025 20:34 | AZN | AstraZeneca makes USD570 million investment in Canada in pipeline push | Alliance |
20.01.2025 09:56 | ABDP, SFR, SYNT | LONDON BROKER RATINGS: Jefferies raises Spirax; Peel Hunt cuts Grainger | Alliance |
20.01.2025 08:38 | AZN | AstraZeneca and Daiichi's Datroway wins US FDA breast cancer approval | Alliance |
20.01.2025 07:00 | AZN | Dato-DXd approved in US for HR+ breast cancer | RNS |
17.01.2025 08:16 | AZN | AstraZeneca's Calquence gets US approval for mantle cell lymphoma | Alliance |
17.01.2025 07:00 | AZN | Calquence combination approved in US for 1L MCL | RNS |
14.01.2025 12:07 | AZN, HCM | IN BRIEF: Hutchmed lung cancer treatment Orpathys approved in China | Alliance |
13.01.2025 09:37 | DAL, THS, WISE | LONDON BROKER RATINGS: Deutsche Bank cuts Direct Line to 'hold' | Alliance |
13.01.2025 09:19 | AZN | AstraZeneca and Daiichi Sankyo cheer priority US review of cancer drug | Alliance |
09.01.2025 11:25 | AZN | AstraZeneca breast cancer drug Lynparza given green light for NHS use | Alliance |
02.01.2025 15:00 | AZN | Total Voting Rights | RNS |
02.01.2025 10:46 | AZN, HCM | Hutchmed China disposes of 45% stake in Shanghai joint venture | Alliance |
27.12.2024 09:11 | AZN, SYNC | Syncona investee sells assets to AstraZeneca for USD12 million | Alliance |
24.12.2024 08:20 | AZN | AstraZeneca and Daiichi withdraw EU application for lung cancer drug | Alliance |
24.12.2024 07:00 | AZN | Dato-DXd NSQ NSCLC application withdrawn in EU | RNS |
23.12.2024 10:13 | AZN | AstraZeneca receives EU approval for Tagrisso lung cancer treatment | Alliance |
23.12.2024 07:00 | AZN | Tagrisso approved in EU based on LAURA trial | RNS |
18.12.2024 12:44 | AZN | PRESS: AstraZeneca sees sales slump in China after arrest of exec - FT | Alliance |
16.12.2024 07:00 | AZN | Directorate Change | RNS |
13.12.2024 10:04 | AZN, HCM | IN BRIEF: Hutchmed to get Takeda milestone payment | Alliance |
11.12.2024 19:40 | AZN | IN BRIEF: Merck and AstraZeneca unveil long-term Lynparza results | Alliance |
09.12.2024 09:09 | AZN | AstraZeneca, Daiichi Sankyo hail US breakthrough therapy designation | Alliance |
05.12.2024 19:52 | SURE, CLC, EMVC | EARNINGS AND TRADING: Synectics deal wins; TruFin to beat expectations | Alliance |
05.12.2024 09:46 | AZN | AstraZeneca touts US FDA approval for small cell lung cancer treatment | Alliance |
05.12.2024 07:00 | AZN | Imfinzi approved in US for limited-stage SCLC | RNS |
04.12.2024 21:37 | AZN | TOP NEWS: AstraZeneca appoints replacement for detained China boss | Alliance |
04.12.2024 13:45 | AZN | AstraZeneca appoints Iskra Reic EVP International | RNS |
02.12.2024 15:05 | AZN | Block listing Interim Review | RNS |
02.12.2024 15:00 | AZN | Total Voting Rights | RNS |
25.11.2024 08:51 | AZN | TOP NEWS: AstraZeneca hails positive Truqap data on prostate cancer | Alliance |
25.11.2024 07:00 | AZN | Truqap improved rPFS in advanced prostate cancer | RNS |
20.11.2024 16:00 | AZN | Director/PDMR Shareholding | RNS |